Cargando…

High variability in baseline urinary free cortisol values in patients with Cushing’s disease

OBJECTIVE: Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing’s syndrome. Because there are few data on UFC variability in patients with active Cushing’s disease, we analysed baseline UFC in a large patient cohort with moderate-to-severe Cushing’s disease and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersenn, S, Newell-Price, J, Findling, J W, Gu, F, Maldonado, M, Sen, K, Salgado, L R, Colao, A, Biller, B M K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231220/ https://www.ncbi.nlm.nih.gov/pubmed/23746264 http://dx.doi.org/10.1111/cen.12259

Ejemplares similares

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome
por: Vega-Beyhart, Arturo, et al.
Publicado: (2022)

Diagnosis of Cushing's disease in a patient with consistently normal urinary free cortisol levels: a case report
por: Moloney, Kelley J., et al.
Publicado: (2016)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

MON-172 Comparison of a Late-night Salivary Cortisol Immunoassay and a Cortisol and Cortisone LCMS Assay in Patients with Cushing’s Disease
por: Kannankeril, Joshua, et al.
Publicado: (2020)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

RF21 | PSAT99 Urinary adrenal steroidome modifications by Ketoconazole and Metyrapone alter the urinary free cortisol immunoassay reliability in Cushing Syndrome
por: Vega-Beyhart, Arturo, et al.
Publicado: (2022)

Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome
por: Kannankeril, Joshua, et al.
Publicado: (2020)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
por: Fleseriu, Maria, et al.
Publicado: (2013)

Comparison of Direct and Extraction Immunoassay Methods With Liquid Chromatography-Tandem Mass Spectrometry Measurement of Urinary Free Cortisol for the Diagnosis of Cushing’s Syndrome
por: Mu, Danni, et al.
Publicado: (2024)

Diagnosis of cyclic Cushing syndrome using the morning urine free cortisol to creatinine ratio
por: Jang, Yi Sun, et al.
Publicado: (2016)

Cushing Mortality in Remission: Not Out of the Woods
por: Kelsall, Alan, et al.
Publicado: (2022)

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
por: Schopohl, Jochen, et al.
Publicado: (2014)

Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?
por: Casals, Gregori, et al.
Publicado: (2020)

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome
por: Newell-Price, John, et al.
Publicado: (2020)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Recognition of Nonneoplastic Hypercortisolism in the Evaluation of Patients With Cushing Syndrome
por: Findling, James W, et al.
Publicado: (2023)

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
por: He, Xin, et al.
Publicado: (2022)

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report
por: Oronsky, Neil, et al.
Publicado: (2017)

Cortisol and Phosphate Homeostasis: Cushing’s Syndrome Is Associated With Reversible Hypophosphatemia
por: Bosman, Ariadne, et al.
Publicado: (2021)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Intraocular pressure and its correlation with midnight plasma cortisol level in Cushing's disease and other endogenous Cushing's syndrome
por: Mishra, Priyadarshini, et al.
Publicado: (2017)

The frequency of Cushing’s disease, ACTH-independent Cushing’s syndrome and autonomous cortisol secretion among Turkish patients with obesity
por: Atar, Resit Volkan, et al.
Publicado: (2020)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

Adrenocorticotropic Hormone-Independent Cushing Syndrome with Bilateral Cortisol-Secreting Adenomas
por: Ku, Eu Jeong, et al.
Publicado: (2013)

The Utility of Preoperative ACTH/Cortisol Ratio for the Diagnosis and Prognosis of Cushing's Disease
por: Selek, Alev, et al.
Publicado: (2018)

Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
por: Fleseriu, Maria
Publicado: (2020)

Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children
por: Ueland, Grethe Å, et al.
Publicado: (2021)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37g3sidvb6sli1svpkr49ft8um